

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 34622/US
		U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <div style="text-align: center; font-size: 1.2em;"> 10/501053 <small>Not Applicable</small> </div>
INTERNATIONAL APPLICATION NO. PCT/CN03/00003	INTERNATIONAL FILING DATE 02/01/2003	PRIORITY DATE CLAIMED 11/01/2002
TITLE OF INVENTION HUMAN HEPATOMA-DERIVED GROWTH FACTOR 5, ITS ENCODING SEQUENCE, METHOD FOR PRODUCING IT AND THE USES THEREOF		
APPLICANT(S) FOR DO/EO/US YU, LONG; TANG, LISHA; GUO, ZEKUN; ZHANG, PINGZHAO; DONG, YIMIN		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> An English translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> are attached hereto (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> had been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
Items 11 to 20. below concern document(s) or information included:		
<ol style="list-style-type: none"> 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 – 1.825 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4) 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: Submission under 37 C.F.R. 3.73(b); and Power of Attorney; Application Data Sheet; a check for \$580.00; and Postcard. 		

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.1) 107501053 Not Applicable		INTERNATIONAL APPLICATION NO. PCT/CN03/00003		ATTORNEY'S DOCKET NUMBER 34622/US	
--	--	---	--	--------------------------------------	--

21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO..... \$1080.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..... \$920.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... \$770.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... \$730.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)..... \$100.00 <div style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div>				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	10 -20 =	0	x \$18.00	\$0.00	
Independent claims	3 -3 =	0	x \$86.00	\$0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$290.00	\$0.00
TOTAL OF ABOVE CALCULATIONS =				\$1080.00	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$540.00	
SUBTOTAL =				\$540.00	
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30				\$0.00	
TOTAL NATIONAL FEE =				\$540.00	
Fee for recording the enclose assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$40.00	
TOTAL FEES ENCLOSED =				\$580.00	
				Amount to be refunded:	\$
				charged:	\$

a. ☒ A check in the amount of \$580.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. 04-1420 in the amount of \$_____ to cover the above fees.
 A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment
 To Deposit Account No. 04-1420 A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Min (Amy) S. Xu
 Dorsey & Whitney LLP
 Intellectual Property Department
 Suite 1500
 50 South Sixth Street
 Minneapolis, MN 55402-1498

July 9, 2004
 Date

Signature

Min (Amy) S. Xu
 Name

39,536
 Registration Number

10/501053

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Applicant(s): Long, Yu

Docket No. 09 JUL 2004
Rec'd PCT/PTO 34622/USSerial No.
UnknownFiling Date
HerewithExaminer
UnknownGroup Art Unit
UnknownInvention: **Human Hepatoma-Derived Growth Factor 5, Its Encoding Sequence, Method For Producing It and The Uses Thereof**

I hereby certify that the following correspondence:

Transmittal Letter to the US (DO/EO/US)(2pgs); Application(29pgs); Declaration (3pgs); IDS(1pg); PTO Form 1449(1pg) -in duplicate; 6 Cited References; Assignment Documents (2pgs); Preliminary Amendment (5pgs); Communication for Sequence Listing (1pg); Copy of Sequence Listing (5pgs); 3.73(b) (1pg); Power of Attorney (1pg); Diskette; a check for \$580; and a Postcard

(Identify type of correspondence)


is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

July 9, 2004

(Date)

Brian Ballard

(Typed or Printed Name of Person Mailing Correspondence)



(Signature of Person Mailing Correspondence)

EV325424689US

("Express Mail" Mailing Label Number)

Note: Each paper must have its own certificate of mailing.

10/501053

DT04 Rec'd PCT/PTO 09 JUL 2004

Docket: 34622/US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Yu, Long	Examiner:	Unknown
Appln. No.:	Unknown	Group Art	
Filed:	Herewith	Unit:	Unknown
	Human Hepatoma-Derived Growth Factor 5, Its		
	Encoding Sequence, Method for Producing It and		
Title:	The Uses Thereof		

COMMUNICATION UNDER 37 C.F.R. § 1.821

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

A paper copy of the SEQUENCE LISTING, to conform the above-referenced application to the requirements of 37 C.F.R. §§ 1.821 through 1.825, is submitted herewith. In accordance with 37 C.F.R. § 1.821(e), a copy of the above-submitted SEQUENCE LISTING in ASCII computer readable form is also submitted herewith.

Respectfully submitted,

DORSEY & WHITNEY LLP
Customer Number 25763

Date: July 9, 2004

By: 
Min (Amy) S. Xu, (Reg. No. 39,536)
Intellectual Property Department
Suite 1500, 50 South Sixth Street
Minneapolis, MN 55402-1498
(612) 752-7367